CycloME: open-label phase II cyclophosphamide study
Rekeland IG et al. · 2020 · Frontiers in Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Six IV infusions of 600–700 mg/m² at four-week intervals. The primary response measure was based on self-reported symptoms.
Dose, route and schedule
Six IV infusions of 600–700 mg/m² at four-week intervals. The primary response measure was based on self-reported symptoms.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported response | 22/40 (55.0%) met the study’s fatigue-response definition. | |
| Physical function | Mean SF-36 physical function rose from 33.0 to 51.5 at 18 months. | |
| Serious adverse events | 11 serious events in eight participants; the paper reports one suspected unexpected serious adverse reaction involving aggravated POTS. |
The lack of a control group prevents attribution. Follow-up reports reuse this cohort.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The lack of a control group prevents attribution. Follow-up reports reuse this cohort.
Related publications may cover the same research program or participants.
Source access
Six IV infusions of 600–700 mg/m² at four-week intervals. The primary response measure was based on self-reported symptoms.
Source reviewed 2026-11-12.
Citation and original source
Original source: Rekeland IG et al.. CycloME: open-label phase II cyclophosphamide study Frontiers in Medicine 2020.
Molekul research summary: https://molekul.io/research/cyclophosphamide-cyclome-2020. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry